Literature DB >> 35529051

Clinical challenges treating Stenotrophomonas maltophilia infections: an update.

Maria F Mojica1,2,3,4, Romney Humphries5, John J Lipuma6, Amy J Mathers7,8, Gauri G Rao9, Samuel A Shelburne10,11,12, Derrick E Fouts13, David Van Duin14, Robert A Bonomo2,3,15,16,17.   

Abstract

Stenotrophomonas maltophilia is a non-fermenting, Gram-negative bacillus that has emerged as an opportunistic nosocomial pathogen. Its intrinsic multidrug resistance makes treating infections caused by S. maltophilia a great clinical challenge. Clinical management is further complicated by its molecular heterogeneity that is reflected in the uneven distribution of antibiotic resistance and virulence determinants among different strains, the shortcomings of available antimicrobial susceptibility tests and the lack of standardized breakpoints for the handful of antibiotics with in vitro activity against this microorganism. Herein, we provide an update on the most recent literature concerning these issues, emphasizing the impact they have on clinical management of S. maltophilia infections. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy 2022.

Entities:  

Year:  2022        PMID: 35529051      PMCID: PMC9071536          DOI: 10.1093/jacamr/dlac040

Source DB:  PubMed          Journal:  JAC Antimicrob Resist        ISSN: 2632-1823


  266 in total

1.  A TEM-2beta-lactamase encoded on an active Tn1-like transposon in the genome of a clinical isolate of Stenotrophomonas maltophilia.

Authors:  M B Avison; C J von Heldreich; C S Higgins; P M Bennett; T R Walsh
Journal:  J Antimicrob Chemother       Date:  2000-12       Impact factor: 5.790

2.  Discrepancies between various methods in susceptibility testing and epidemiological analysis of Stenotrophomonas maltophilia clinical isolates.

Authors:  Aikaterini Masgala; Irene Galani; Maria Souli; Helen Giamarellou
Journal:  Cent Eur J Public Health       Date:  2010-06       Impact factor: 1.163

3.  NagZ-dependent and NagZ-independent mechanisms for β-lactamase expression in Stenotrophomonas maltophilia.

Authors:  Yi-Wei Huang; Rouh-Mei Hu; Cheng-Wen Lin; Tung-Ching Chung; Tsuey-Ching Yang
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

Review 4.  Cefiderocol: A new Antimicrobial for Complicated Urinary Tract Infection (CUTI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE).

Authors:  Suparna Chatterjee; Dwaipayan Sarathi Chakraborty; Shouvik Choudhury; Sandeep Lahiry
Journal:  Curr Drug Res Rev       Date:  2022

5.  Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients.

Authors:  V Marchac; A Equi; C Le Bihan-Benjamin; M Hodson; A Bush
Journal:  Eur Respir J       Date:  2004-01       Impact factor: 16.671

6.  Community acquired Stenotrophomonas maltophilia discitis: Diagnosis aided by shotgun metagenomic sequencing.

Authors:  Gang Wang; Nannan Xu; Lulu Yang; Feng Zheng; Lintao Sai; Jiale Zhou; Shangxin Yang
Journal:  Int J Infect Dis       Date:  2019-01-23       Impact factor: 3.623

7.  Risk Factors Associated with Stenotrophomonas maltophilia Bacteremia: A Matched Case-Control Study.

Authors:  Kosuke Sumida; Yong Chong; Noriko Miyake; Tomohiko Akahoshi; Mitsuhiro Yasuda; Nobuyuki Shimono; Shinji Shimoda; Yoshihiko Maehara; Koichi Akashi
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

Review 8.  Stenotrophomonas maltophilia as an Emerging Ubiquitous Pathogen: Looking Beyond Contemporary Antibiotic Therapy.

Authors:  Anthony A Adegoke; Thor A Stenström; Anthony I Okoh
Journal:  Front Microbiol       Date:  2017-11-30       Impact factor: 5.640

9.  Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone-resistant strains.

Authors:  Eun Jin Kim; Yong Chan Kim; Jin Young Ahn; Su Jin Jeong; Nam Su Ku; Jun Yong Choi; Joon-Sup Yeom; Young Goo Song
Journal:  BMC Infect Dis       Date:  2019-08-28       Impact factor: 3.090

Review 10.  Iron and Virulence in Stenotrophomonas Maltophilia: All We Know So Far.

Authors:  V Kalidasan; Narcisse Joseph; Suresh Kumar; Rukman Awang Hamat; Vasantha Kumari Neela
Journal:  Front Cell Infect Microbiol       Date:  2018-11-12       Impact factor: 5.293

View more
  1 in total

1.  Activity of Delafloxacin and Levofloxacin against Stenotrophomonas maltophilia at Simulated Plasma and Intrapulmonary pH Values.

Authors:  Alesia Vialichka; Mark Biagi; Kevin Meyer; Tiffany Wu; Aisha Shajee; Xing Tan; Eric Wenzler
Journal:  Microbiol Spectr       Date:  2022-07-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.